We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
As drugs, devices and other healthcare products become more innovative and complex, and as development costs increase, working collaboratively becomes more important.
According to analysts at RBC Capital Markets, Sarepta Therapeutics, Sage Therapeutics and Loxo Oncology are the most likely takeover targets among biotechnology firms in 2019, reported Investor's Business Daily. Sarepta is working on a gene therapy in a m
The UK pharmaceutical industry is pressing ahead with M&A activity and is “geared to weather any disruption due to Brexit”, suggest results of a recent survey by EY.